Catherine M. Szyman - Jan 14, 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Critical Care
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Jan 14, 2022
Transactions value $
-$977,663
Form type
4
Date filed
1/14/2022, 06:16 PM
Previous filing
Dec 17, 2021
Next filing
Feb 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $218K +10K +36.48% $21.76 37.4K Jan 14, 2022 Direct F1
transaction EW Common Stock Sale -$134K -1.12K -2.98% $120.01 36.3K Jan 14, 2022 Direct F1, F2
transaction EW Common Stock Sale -$1.06M -8.88K -24.47% $119.47 27.4K Jan 14, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -10K -10.71% $0.00 83.4K Jan 14, 2022 Common Stock 10K $21.76 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $119.960 to $120.085. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $118.960 to $119.950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.